Life Science Reit Plc ( (GB:LABS) ) just unveiled an announcement.
Life Science REIT plc has announced a strategic review to explore options for maximizing shareholder value, including a potential sale or managed wind down, amid challenges like high inflation and interest rates affecting the REIT sector. The company has suspended dividends due to delays in leasing activity and is negotiating reduced fees with its investment advisor to better align interests with shareholders. The strategic review will include a formal sale process, with Panmure Liberum appointed as the financial adviser, but there is no certainty of an offer being made.
More about Life Science Reit Plc
Life Science REIT plc is the UK’s only listed property business focused on the life science sector, investing in high-quality assets in research and development hubs like Oxford, Cambridge, and London’s Knowledge Quarter. The company leases properties primarily to life science sector occupiers, deriving 55% of its rent from them.
YTD Price Performance: 2.11%
Average Trading Volume: 736,207
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £128.5M
See more insights into LABS stock on TipRanks’ Stock Analysis page.